Mark Dumenil new CEO of CMA Microdialysis
Mark Dumenil new CEO of CMA Microdialysis Mark Dumenil has been appointed as CEO of CMA Microdialysis, a subsidiary of Skanditek. Mark Dumenil's experience in business development within medical de-vices will be valuable for CMA Microdialysis in the transformation from research com-pany to a commercially oriented medical device company. Mark Dumenil brings to the company over 15 years of experience in medical devices at Johnson & Johnson and CR Bard. Before joining CMA Microdialysis, he held the position of European Vice President Oncology at the Ethicon Endo Surgery division of Johnson & Johnson, having previously been European Director of New Business Development and Growth Technologies. Mark Dumenil, 49 years, qualified as Chartered Accountant and holds a degree in accounting from the University of the City of London. In addition to finance he has acquired experience in marketing, operations and licensing and acquisitions during his career. The priorities of the new CEO will be to transform CMA from a research company into an in-ternational, commercially orientated medical device company based on strong science. The appointment of Mark Dumenil as CEO will allow former CEO, professor Urban Ungerstedt to concentrate more extensively as Chief Scientific Officer on the company's product develop-ment, as well as developing clinical and medical outcomes studies for microdialysis. CMA is the market leader in the development and marketing of microdialysis products. Microdi-alysis is a proprietary technology that reveals, among other things, ischemia, a life-threatening condition that arises when circulation of blood in an organ is reduced. Stockholm, April 2, 2001 SKANDITEK INDUSTRIFÖRVALTNING AB (publ) For further information, please contact: Patrik Tigerschiöld, president, phone +46 (0)8 614 00 20, mobile +46 (0)70 777 71 90, e-mail patrik.tigerschiold@skanditek.se. Skanditek is an industrial holding company owning stock in Swedish unlisted and listed companies. Our business concept is to be an active and long-term stockholder and to further the portfolio companies' development by provid-ing industrial and financial competence at board and management level. The portfolio comprises some twenty hold-ings within the areas electronics, information technology, biotechnology and services. The major holdings are in Axis (14%), LGP Telecom Holding (10%), Mydata Automation (39%), PartnerTech (26%), Vellinge Electronics (100%) and Vitrolife (45%). Skanditek is listed on the OM Stockholm Exchange's O list and has a market value of about SEK 2 billion. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/04/02/20040930BIT20700/wkr0001.pdf